Supplementary Tables S1-10 from Reprogramming of the ERRα and ERα Target Gene Landscape Triggers Tamoxifen Resistance in Breast Cancer

Supplementary Tables S1-10. Supplementary Table S1: Clinico-pathological features of primary treatment-naive and relapsed tamoxifen-resistant breast carcinomas assessed by routine pathological evaluation. Supplementary Table S2: Antibodies for Western blot analyses, ChIP and immunohisto-chemistry. Supplementary Table S3: Primer sequences for qRT-PCR (5'-3'). Supplementary Table S4 : p-values. Supplementary Table S5: Top differentially expressed transcripts between MCF-7 #Wt and #TamR. Supplementary Table S6: ERalpha, ERRalpha and AIB1 target genes identified by ChIP-Seq and gene expression profiling (EP) in MCF-7 #Wt vs. # TamR cells. Supplementary Table S7: ERalpha and ERRalpha target genes identified by ChIP-Seq and gene expression profiling in MCF-7 cells. Supplemetary Table S8: Enrichment of functional categories for ERalpha and ERRalpha target genes in #TamR. Supplementary Table S9: Pairwise relationship between ERRalpha and co-variables in ERalpha-positive breast carcinomas (tumor set III, n=1041). Supplementary Table S10: Effects of co-variables on patient survival in tamoxifen-treated primary breast tumors (GSE9893) stratified to grade and PR status.